ADCT

The LOTIS-5 results place ADC Therapeutics on a definitive regulatory trajectory, with a pre-sBLA meeting scheduled for August and a submission planned for late 2026. While the efficacy data is statistically significant, the investment thesis now hinges on whether the FDA views the increased safety risks as an acceptable trade-off for improved durability of response. The company's focus on cost reduction and its cash runway extending into 2028 provide some operational breathing room as it navigates this high-stakes regulatory window.

The Q1 2026 filing presents a company at a crossroads, balancing promising commercial traction against a restrictive debt profile. On one hand, the 15.1% increase in product revenue and the successful reduction of the R&D burn rate suggest that the 2025 restructuring is working. The company is leaner and more focused on its primary asset, ZYNLONTA, which is showing genuine market demand in the U.S. However, the structural risks are significant. The reliance on high-cost debt and the volatility of total revenue—which remains dependent on sporadic milestone payments—create a fragile equilibrium. Investors must weigh the potential for ZYNLONTA to move into earlier treatment lines against the risk of further equity dilution or liquidity crises as the company services its massive royalty and loan obligations. The ultimate trajectory depends on whether commercial scaling can outpace the cost of its capital.